Skip to main content

Table 2 Demographic and baseline disease characteristics according to DAS28 response category at the end of period 1

From: The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis

  PRESERVE, N = 594 PRIZE, N = 192 T2T, N = 331
Sustained deep remission
n = 133 (22%)
Deep remission
n = 136 (23%)
Sustained remission
n = 96 (16%)
Remission
n = 116 (20%)
LDA
n = 113 (19%)
Sustained deep remission
n = 67 (35%)
Deep remission
n = 40 (21%)
Sustained remission
n = 39 (20%)
Remission
n = 46 (24%)
Sustained deep remission
n = 13 (4%)
Deep remission n = 30 (9%) Sustained remission
n = 10 (3%)
Remission
n = 70 (21%)
LDA
n = 208 (63%)
Demographic characteristics
 Age, years, mean (SD) 43.6 (12.6) 47.9 (12.1) 47.1 (12.0) 47.9 (12.3) 51.8 (10.3)*** 43.7 (14.4) 54.1 (13.7) 49.7 (13.3) 53.3 (13.7)** 41.1 (13.5) 44.4 (14.4) 52.3 (11.5) 44.3 (11.7) 47.8 (12.1)*
 Female, n (%) 97 (73) 111 (82) 82 (85) 98 (84) 91 (81) 41 (61) 27 (68) 25 (64) 31 (67) 9 (69) 22 (73) 9 (90) 57 (81) 182 (88)*
 BMI, kg/m2, mean (SD) 25.0 (3.9) 25.5 (4.2) 25.8 (5.3) 25.2 (4.3) 26.4 (5.1) 24.4 (3.5) 26.5 (4.9) 26.3 (5.0) 26.8 (5.0)** 24.4 (4.6) 26.5 (4.7) 23.6 (3.1) 28.4 (5.9) 26.8 (5.3)
  BMI, female 24.6 (3.8) 25.3 (4.3) 25.8 (5.4) 24.9 (4.3) 26.7 (5.2)* 23.2 (3.4) 25.5 (4.6) 25.7 (4.4) 25.6 (4.9)* 25.0 (4.6) 26.7 (5.0) 23.5 (3.2) 28.4 (6.0) 26.7 (5.4)
  BMI, male 26.3 (4.2) 26.1 (3.8) 25.9 (4.9) 26.7 (4.3) 25.4 (4.6) 26.2 (3.1) 28.7 (4.8) 27.5 (5.9) 29.1 (4.3) 23.2 (5.1) 26.0 (3.8) 24.6 28.5 (5.8) 27.3 (4.9)
Prior treatmenta
 Corticosteroid(s), n (%) 76 (57) 76 (56) 56 (58) 77 (66) 70 (62) 22 (33) 18 (45) 17 (44) 22 (48) 9 (69) 17 (57) 6 (60) 52 (74) 140 (67)
 NSAID(s), n (%) 98 (74) 103 (76) 68 (71) 91 (78) 85 (75) 47 (70) 27 (68) 27 (69) 29 (63) 11 (85) 19 (63) 6 (60) 40 (57) 144 (69)
 DMARD(s),b n (%) 37 (28) 41 (30) 18 (19) 29 (25) 23 (20) 11 (16) 11 (28) 5 (13) 6 (13) 4 (31) 10 (33) 2 (20) 38 (54) 65 (31)
 Number of DMARD(s)b,c mean (min, max) 1.3 (1, 3) 1.3 (1, 3) 1.2 (1, 3) 1.3 (1, 5) 1.2 (1, 2) 1.0 (1, 1) 1.0 (1, 1) 1.0 (1, 1) 1.0 (1, 1) 1.3 (1, 2) 1.3 (1, 2) 1.0 (1, 1) 1.5 (1, 3) 1.3 (1, 3)
 Disease characteristics
 Duration of disease, mean (SD) 6.3 (6.8) years 6.6 (6.2) years 7.3 (6.5) years 7.3 (7.7) years 6.7 (7.1) years 6.7 (2.8) months 7.4 (3.2) months 6.3 (2.6) months 7.0 (3.0) months 7.9 (6.2) years 6.3 (5.6) years 8.0 (4.8) years 8.3 (6.8) years 8.4 (7.5) years
 RF+, n (%) 96 (72) 94 (69) 77 (80) 84 (72) 78 (69) 44 (66) 25 (63) 18 (46) 24 (52) 9 (69) 23 (77) 9 (90) 59 (84) 175 (84)
 aCCP antibody+, n (%) 100 (75) 99 (73) 82 (85) 99 (85) 85 (75) 47 (70) 27 (68) 23 (59) 29 (63) 9 (69) 24 (80) 10 (100) 49 (70) 171 (82)
 ESR, mm/h, mean (SD) 17.9 (10.6) 20.8 (13.0) 24.4 (12.9) 22.7 (11.8) 22.1 (13.9)** 30.1 (22.3) 36.3 (24.3) 38.4 (20.6) 31.7 (19.1) 25.5 (13.8) 37.6 (21.7) 32.1 (15.1) 43.7 (27.7) 50.8 (24.7)***
 CRP, mg/L, mean (SD) 10.7 (13.8) 10.5 (12.1) 11.4 (14.2) 11.8 (14.7) 14.2 (20.4) 13.4 (18.6) 19.8 (27.1) 16.3 (24.3) 13.8 (16.6) 21.5 (18.2) 22.0 (16.7) 14.9 (11.9) 21.1 (19.9) 24.0 (29.3)
Disease activity and patient-reported outcomes, mean (SD)
 TJC (0–28) 4.9 (2.8) 5.2 (2.4) 4.7 (2.8) 4.8 (2.8) 5.5 (3.5) 12.5 (5.8) 13.3 (6.8) 13.4 (6.8) 14.3 (7.2) 10.1 (6.6) 12.3 (6.7) 13.7 (6.4) 14.1 (6.7) 14.3 (6.1)*
 SJC (0–28) 3.9 (2.7) 3.8 (2.5) 4.0 (2.7) 3.6 (2.4) 4.4 (3.1) 8.8 (5.0) 11.0 (6.0) 11.1 (6.3) 11.0 (5.2)* 9.5 (5.4) 9.9 (5.9) 10.5 (5.5) 10.7 (5.4) 10.6 (5.5)
 DAS28-ESR, mean (SD) 4.2 (0.5) 4.3 (0.4) 4.4 (0.4) 4.4 (0.4) 4.4 (0.5)*** 5.6 (1.0) 6.0 (1.1) 6.0 (1.1) 5.9 (1.1) 5.5 (1.3) 6.0 (1.2) 6.1 (0.9) 6.3 (1.1) 6.5 (0.9)***
 CDAI (0–76) 17.8 (4.9) 17.4 (4.6) 17.3 (5.2) 17.5 (4.6) 18.9 (5.6) 31.2 (15.0) 35.3 (12.5) 38.1 (11.0) 38.6 (12.7) 38.3 (11.4)*
 PGA (0–10) 4.1 (1.4) 3.9 (1.3) 4.0 (1.3) 4.2 (1.3) 4.1 (1.2) 5.2 (1.6) 5.8 (1.5) 5.8 (1.8) 5.5 (1.5) 6.1 (1.7) 6.8 (1.3) 7.2 (1.0) 6.9 (1.6) 6.7 (1.3)
 HAQ (0–3) 0.9 (0.5) 1.2 (0.6) 1.1 (0.5) 1.1 (0.6) 1.2 (0.5)* 1.1 (0.5) 1.3 (0.6) 1.2 (0.7) 1.1 (0.7) 1.0 (0.8) 1.3 (0.6) 1.3 (0.7) 1.6 (0.7) 1.5 (0.6)**
  1. aCCP anti-cyclic citrullinated peptide, BMI body mass index, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, DAS28-ESR Disease Activity Score in 28 joints calculated with erythrocyte sedimentation rate, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire, LDA low disease activity, MTX methotrexate, NSAID nonsteroidal anti-inflammatory drug, PGA physician global assessment, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation, SJC swollen joint count, TJC tender joint count
  2. aIn PRESERVE, “prior” was within 6 months of screening (for DMARDs not including MTX), within 28 days of screening or baseline (for glucocorticoids), or concurrent treatment with ≥ 1 NSAID at baseline; in PRIZE, “prior” was 28 days before screening (for NSAIDs and corticosteroids) and any time before screening (for DMARDs); in T2T, “prior” was 6 months before screening (for MTX and DMARDs,) or 4 weeks before screening (for NSAIDs and corticosteroids)
  3. bConventional DMARDs other than MTX
  4. cMean, minimum, and maximum were calculated only from patients who did have prior DMARD(s)
  5. *P < 0.05 across response categories; **P < 0.01 across response categories; ***P < 0.001 across response categories